JMT206 / CSPC Pharma - LARVOL DELTA

Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P1 trial • Obesity

Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P1 trial

CSPC Pharmaceutical has received approval from the U.S. Food and Drug Administration to conduct clinical trials for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody JMT206 in the United States, according to a filing with the Hong Kong Stock Exchange. (Investing.com)

IND • Obesity

CSPC Pharmaceutical’s JMT206 Receives Clinical Trial Approval in China (TipRanks)

New trial • Obesity